These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 28423358)
1. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358 [TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
4. Involvement of DPP9 in gene fusions in serous ovarian carcinoma. Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231 [TBL] [Abstract][Full Text] [Related]
5. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895 [TBL] [Abstract][Full Text] [Related]
7. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711 [TBL] [Abstract][Full Text] [Related]
8. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma. Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Cao Y; Shi H; Ren F; Jia Y; Zhang R Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469 [TBL] [Abstract][Full Text] [Related]
13. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340 [TBL] [Abstract][Full Text] [Related]
14. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. Yoffou PH; Edjekouane L; Meunier L; Tremblay A; Provencher DM; Mes-Masson AM; Carmona E PLoS One; 2011; 6(6):e20705. PubMed ID: 21695196 [TBL] [Abstract][Full Text] [Related]
15. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer. Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536 [TBL] [Abstract][Full Text] [Related]
16. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Guo Y; Fu P; Zhu H; Reed E; Remick SC; Petros W; Mueller MD; Yu JJ Oncol Rep; 2012 Jan; 27(1):286-92. PubMed ID: 21971700 [TBL] [Abstract][Full Text] [Related]
17. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9. Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653 [TBL] [Abstract][Full Text] [Related]
19. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834 [TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis in type I epithelial ovarian cancer. Sadłecki P; Walentowicz-Sadłecka M; Grabiec M Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]